Nice try but if you read the whole article you would see that the problem primarily lies in the quality of the manufactured drugs not necessarily the clinical trials. I would suggest peer reviewed nature of a2 trials will standup
- Forums
- ASX - By Stock
- A2M
- 2 new studies from A2MC
2 new studies from A2MC, page-28
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$5.58 |
Change
-0.060(1.06%) |
Mkt cap ! $4.058B |
Open | High | Low | Value | Volume |
$5.62 | $5.63 | $5.57 | $1.062M | 189.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 6993 | $5.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.59 | 1814 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 6136 | 5.580 |
9 | 24807 | 5.570 |
8 | 15006 | 5.560 |
9 | 44380 | 5.550 |
5 | 12813 | 5.540 |
Price($) | Vol. | No. |
---|---|---|
5.590 | 4523 | 9 |
5.600 | 10083 | 12 |
5.610 | 35719 | 18 |
5.620 | 29908 | 12 |
5.630 | 13425 | 7 |
Last trade - 11.52am 12/09/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |